RapamycinFungusV1, Main, Exploration, bibRecord, 000183

Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.

Identifieur interne : 000183 ( Main/Exploration ); précédent : 000182; suivant : 000184

Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.

Auteurs : Marina Pontelo Cristelli [Brésil] ; Claudia Rosso Felipe [Brésil] ; Paulo Sergio De Souza Prizmic [Brésil] ; Vega Figueiredo Dourado De Azevedo [Brésil] ; Laila Almeida Viana [Brésil] ; Melissa Gaspar Tavares [Brésil] ; Daniel Wagner De Castro Lima Santos [Brésil] ; Mayara Ivani De Paula [Brésil] ; Jose Osmar Medina-Pestana [Brésil] ; Helio Tedesco-Silva Junior [Brésil]

Source :

Clinical transplantation [ 1399-0012 ] ; 2019.

RBID : pubmed:31400155

Descripteurs français

KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Brésil (épidémiologie), Complications postopératoires (MeSH), Cytomegalovirus (isolement et purification), Facteurs de risque (MeSH), Femelle (MeSH), Humains (MeSH), Immunosuppresseurs (administration et posologie), Incidence (MeSH), Infections à cytomégalovirus (microbiologie), Infections à cytomégalovirus (traitement médicamenteux), Infections à cytomégalovirus (épidémiologie), Mâle (MeSH), Prednisone (administration et posologie), Pronostic (MeSH), Rejet du greffon (diagnostic), Rejet du greffon (traitement médicamenteux), Rejet du greffon (étiologie), Survie du greffon (effets des médicaments et des substances chimiques), Sérine-thréonine kinases TOR (antagonistes et inhibiteurs), Sérum antilymphocyte (administration et posologie), Tacrolimus (administration et posologie), Transplantation rénale (effets indésirables), Études de suivi (MeSH), Études rétrospectives (MeSH), Évérolimus (administration et posologie).
MESH :
- administration et posologie : Immunosuppresseurs, Prednisone, Sérum antilymphocyte, Tacrolimus, Évérolimus.
- antagonistes et inhibiteurs : Sérine-thréonine kinases TOR.
- diagnostic : Rejet du greffon.
- effets des médicaments et des substances chimiques : Survie du greffon.
- effets indésirables : Transplantation rénale.
- isolement et purification : Cytomegalovirus.
- microbiologie : Infections à cytomégalovirus.
- traitement médicamenteux : Infections à cytomégalovirus, Rejet du greffon.
- épidémiologie : Brésil, Infections à cytomégalovirus.
- étiologie : Rejet du greffon.
- Adulte, Adulte d'âge moyen, Complications postopératoires, Facteurs de risque, Femelle, Humains, Incidence, Mâle, Pronostic, Études de suivi, Études rétrospectives.
Wicri :
- geographic : Brésil.

English descriptors

KwdEn :
- Adult (MeSH), Antilymphocyte Serum (administration & dosage), Brazil (epidemiology), Cytomegalovirus (isolation & purification), Cytomegalovirus Infections (drug therapy), Cytomegalovirus Infections (epidemiology), Cytomegalovirus Infections (microbiology), Everolimus (administration & dosage), Female (MeSH), Follow-Up Studies (MeSH), Graft Rejection (diagnosis), Graft Rejection (drug therapy), Graft Rejection (etiology), Graft Survival (drug effects), Humans (MeSH), Immunosuppressive Agents (administration & dosage), Incidence (MeSH), Kidney Transplantation (adverse effects), Male (MeSH), Middle Aged (MeSH), Postoperative Complications (MeSH), Prednisone (administration & dosage), Prognosis (MeSH), Retrospective Studies (MeSH), Risk Factors (MeSH), TOR Serine-Threonine Kinases (antagonists & inhibitors), Tacrolimus (administration & dosage).
MESH :
- chemical , administration & dosage : Antilymphocyte Serum, Everolimus, Immunosuppressive Agents, Prednisone, Tacrolimus.
- chemical , antagonists & inhibitors : TOR Serine-Threonine Kinases.
- geographic , epidemiology : Brazil.
- adverse effects : Kidney Transplantation.
- diagnosis : Graft Rejection.
- drug effects : Graft Survival.
- drug therapy : Cytomegalovirus Infections, Graft Rejection.
- epidemiology : Cytomegalovirus Infections.
- etiology : Graft Rejection.
- isolation & purification : Cytomegalovirus.
- microbiology : Cytomegalovirus Infections.
- Adult, Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Postoperative Complications, Prognosis, Retrospective Studies, Risk Factors.

Abstract

OBJECTIVES

To describe the incidence of cytomegalovirus (CMV) infection/disease in kidney transplant recipients receiving an mTOR-inhibitor-containing immunosuppressive regimen without prophylactic CMV treatment.

METHODS

This single-center retrospective cohort analysis included all de novo kidney transplant recipients (09/15/2015-07/31/2017) receiving 3 mg/kg single dose of rabbit antithymocyte globulin induction, tacrolimus, everolimus, and prednisone. Preemptive therapy was initiated only in patients deemed at higher risk for CMV infection: (a) D+/R- CMV patients; (b) after treatment for acute rejection (ARt); and (c) after everolimus discontinuation (EVRd).

RESULTS

Of 230 patients, there were no episodes of CMV disease among 217 (94%) without criteria to initiate preemptive therapy. Of 77 (33.5%) patients initiating preemptive therapy, 13 were D+/R-, 30 were ARt, and 34 were EVRd. The overall incidence of first CMV infection/disease was 6% (46.1% in D+/R-, 13.3% ARt [all patients had also discontinued everolimus], and 11.8% after early [<90 days] EVRd). The incidence of biopsy-proven acute rejection was 5.6%, and median glomerular filtration rate at month 12 was 47 mL/min/1.73m

CONCLUSION

This study suggests that everolimus-containing immunosuppressive regimen reduces the need for preventive strategies for CMV infection in the majority of kidney transplant recipients, reducing antiviral drug-associated toxicities and healthcare-related expenditures.

DOI: 10.1111/ctr.13689
PubMed: 31400155

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000211
to stream Main, to step Curation: 000211

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.</title>
<author><name sortKey="Cristelli, Marina Pontelo" sort="Cristelli, Marina Pontelo" uniqKey="Cristelli M" first="Marina Pontelo" last="Cristelli">Marina Pontelo Cristelli</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Felipe, Claudia Rosso" sort="Felipe, Claudia Rosso" uniqKey="Felipe C" first="Claudia Rosso" last="Felipe">Claudia Rosso Felipe</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Prizmic, Paulo Sergio De Souza" sort="Prizmic, Paulo Sergio De Souza" uniqKey="Prizmic P" first="Paulo Sergio De Souza" last="Prizmic">Paulo Sergio De Souza Prizmic</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="De Azevedo, Vega Figueiredo Dourado" sort="De Azevedo, Vega Figueiredo Dourado" uniqKey="De Azevedo V" first="Vega Figueiredo Dourado" last="De Azevedo">Vega Figueiredo Dourado De Azevedo</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Viana, Laila Almeida" sort="Viana, Laila Almeida" uniqKey="Viana L" first="Laila Almeida" last="Viana">Laila Almeida Viana</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Tavares, Melissa Gaspar" sort="Tavares, Melissa Gaspar" uniqKey="Tavares M" first="Melissa Gaspar" last="Tavares">Melissa Gaspar Tavares</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Wagner De Castro Lima Santos, Daniel" sort="Wagner De Castro Lima Santos, Daniel" uniqKey="Wagner De Castro Lima Santos D" first="Daniel" last="Wagner De Castro Lima Santos">Daniel Wagner De Castro Lima Santos</name>
<affiliation wicri:level="4"><nlm:affiliation>Infectious Disease Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Infectious Disease Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="De Paula, Mayara Ivani" sort="De Paula, Mayara Ivani" uniqKey="De Paula M" first="Mayara Ivani" last="De Paula">Mayara Ivani De Paula</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Medina Pestana, Jose Osmar" sort="Medina Pestana, Jose Osmar" uniqKey="Medina Pestana J" first="Jose Osmar" last="Medina-Pestana">Jose Osmar Medina-Pestana</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Tedesco Silva Junior, Helio" sort="Tedesco Silva Junior, Helio" uniqKey="Tedesco Silva Junior H" first="Helio" last="Tedesco-Silva Junior">Helio Tedesco-Silva Junior</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:31400155</idno>
<idno type="pmid">31400155</idno>
<idno type="doi">10.1111/ctr.13689</idno>
<idno type="wicri:Area/Main/Corpus">000211</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000211</idno>
<idno type="wicri:Area/Main/Curation">000211</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000211</idno>
<idno type="wicri:Area/Main/Exploration">000211</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.</title>
<author><name sortKey="Cristelli, Marina Pontelo" sort="Cristelli, Marina Pontelo" uniqKey="Cristelli M" first="Marina Pontelo" last="Cristelli">Marina Pontelo Cristelli</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Felipe, Claudia Rosso" sort="Felipe, Claudia Rosso" uniqKey="Felipe C" first="Claudia Rosso" last="Felipe">Claudia Rosso Felipe</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Prizmic, Paulo Sergio De Souza" sort="Prizmic, Paulo Sergio De Souza" uniqKey="Prizmic P" first="Paulo Sergio De Souza" last="Prizmic">Paulo Sergio De Souza Prizmic</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="De Azevedo, Vega Figueiredo Dourado" sort="De Azevedo, Vega Figueiredo Dourado" uniqKey="De Azevedo V" first="Vega Figueiredo Dourado" last="De Azevedo">Vega Figueiredo Dourado De Azevedo</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Viana, Laila Almeida" sort="Viana, Laila Almeida" uniqKey="Viana L" first="Laila Almeida" last="Viana">Laila Almeida Viana</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Tavares, Melissa Gaspar" sort="Tavares, Melissa Gaspar" uniqKey="Tavares M" first="Melissa Gaspar" last="Tavares">Melissa Gaspar Tavares</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Wagner De Castro Lima Santos, Daniel" sort="Wagner De Castro Lima Santos, Daniel" uniqKey="Wagner De Castro Lima Santos D" first="Daniel" last="Wagner De Castro Lima Santos">Daniel Wagner De Castro Lima Santos</name>
<affiliation wicri:level="4"><nlm:affiliation>Infectious Disease Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Infectious Disease Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="De Paula, Mayara Ivani" sort="De Paula, Mayara Ivani" uniqKey="De Paula M" first="Mayara Ivani" last="De Paula">Mayara Ivani De Paula</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Medina Pestana, Jose Osmar" sort="Medina Pestana, Jose Osmar" uniqKey="Medina Pestana J" first="Jose Osmar" last="Medina-Pestana">Jose Osmar Medina-Pestana</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Tedesco Silva Junior, Helio" sort="Tedesco Silva Junior, Helio" uniqKey="Tedesco Silva Junior H" first="Helio" last="Tedesco-Silva Junior">Helio Tedesco-Silva Junior</name>
<affiliation wicri:level="4"><nlm:affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP</wicri:regionArea>
<placeName><region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical transplantation</title>
<idno type="eISSN">1399-0012</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Antilymphocyte Serum (administration & dosage)</term>
<term>Brazil (epidemiology)</term>
<term>Cytomegalovirus (isolation & purification)</term>
<term>Cytomegalovirus Infections (drug therapy)</term>
<term>Cytomegalovirus Infections (epidemiology)</term>
<term>Cytomegalovirus Infections (microbiology)</term>
<term>Everolimus (administration & dosage)</term>
<term>Female (MeSH)</term>
<term>Follow-Up Studies (MeSH)</term>
<term>Graft Rejection (diagnosis)</term>
<term>Graft Rejection (drug therapy)</term>
<term>Graft Rejection (etiology)</term>
<term>Graft Survival (drug effects)</term>
<term>Humans (MeSH)</term>
<term>Immunosuppressive Agents (administration & dosage)</term>
<term>Incidence (MeSH)</term>
<term>Kidney Transplantation (adverse effects)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Postoperative Complications (MeSH)</term>
<term>Prednisone (administration & dosage)</term>
<term>Prognosis (MeSH)</term>
<term>Retrospective Studies (MeSH)</term>
<term>Risk Factors (MeSH)</term>
<term>TOR Serine-Threonine Kinases (antagonists & inhibitors)</term>
<term>Tacrolimus (administration & dosage)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Brésil (épidémiologie)</term>
<term>Complications postopératoires (MeSH)</term>
<term>Cytomegalovirus (isolement et purification)</term>
<term>Facteurs de risque (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Immunosuppresseurs (administration et posologie)</term>
<term>Incidence (MeSH)</term>
<term>Infections à cytomégalovirus (microbiologie)</term>
<term>Infections à cytomégalovirus (traitement médicamenteux)</term>
<term>Infections à cytomégalovirus (épidémiologie)</term>
<term>Mâle (MeSH)</term>
<term>Prednisone (administration et posologie)</term>
<term>Pronostic (MeSH)</term>
<term>Rejet du greffon (diagnostic)</term>
<term>Rejet du greffon (traitement médicamenteux)</term>
<term>Rejet du greffon (étiologie)</term>
<term>Survie du greffon (effets des médicaments et des substances chimiques)</term>
<term>Sérine-thréonine kinases TOR (antagonistes et inhibiteurs)</term>
<term>Sérum antilymphocyte (administration et posologie)</term>
<term>Tacrolimus (administration et posologie)</term>
<term>Transplantation rénale (effets indésirables)</term>
<term>Études de suivi (MeSH)</term>
<term>Études rétrospectives (MeSH)</term>
<term>Évérolimus (administration et posologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antilymphocyte Serum</term>
<term>Everolimus</term>
<term>Immunosuppressive Agents</term>
<term>Prednisone</term>
<term>Tacrolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Brazil</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Immunosuppresseurs</term>
<term>Prednisone</term>
<term>Sérum antilymphocyte</term>
<term>Tacrolimus</term>
<term>Évérolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Kidney Transplantation</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sérine-thréonine kinases TOR</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Graft Rejection</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Rejet du greffon</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Graft Survival</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cytomegalovirus Infections</term>
<term>Graft Rejection</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Survie du greffon</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Transplantation rénale</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cytomegalovirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Graft Rejection</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Cytomegalovirus</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Cytomegalovirus</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Infections à cytomégalovirus</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Cytomegalovirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à cytomégalovirus</term>
<term>Rejet du greffon</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Brésil</term>
<term>Infections à cytomégalovirus</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Rejet du greffon</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Postoperative Complications</term>
<term>Prognosis</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Complications postopératoires</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Humains</term>
<term>Incidence</term>
<term>Mâle</term>
<term>Pronostic</term>
<term>Études de suivi</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Brésil</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b>
</p>
<p>To describe the incidence of cytomegalovirus (CMV) infection/disease in kidney transplant recipients receiving an mTOR-inhibitor-containing immunosuppressive regimen without prophylactic CMV treatment.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>This single-center retrospective cohort analysis included all de novo kidney transplant recipients (09/15/2015-07/31/2017) receiving 3 mg/kg single dose of rabbit antithymocyte globulin induction, tacrolimus, everolimus, and prednisone. Preemptive therapy was initiated only in patients deemed at higher risk for CMV infection: (a) D+/R- CMV patients; (b) after treatment for acute rejection (ARt); and (c) after everolimus discontinuation (EVRd).</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>Of 230 patients, there were no episodes of CMV disease among 217 (94%) without criteria to initiate preemptive therapy. Of 77 (33.5%) patients initiating preemptive therapy, 13 were D+/R-, 30 were ARt, and 34 were EVRd. The overall incidence of first CMV infection/disease was 6% (46.1% in D+/R-, 13.3% ARt [all patients had also discontinued everolimus], and 11.8% after early [<90 days] EVRd). The incidence of biopsy-proven acute rejection was 5.6%, and median glomerular filtration rate at month 12 was 47 mL/min/1.73m</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>This study suggests that everolimus-containing immunosuppressive regimen reduces the need for preventive strategies for CMV infection in the majority of kidney transplant recipients, reducing antiviral drug-associated toxicities and healthcare-related expenditures.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31400155</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>09</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-0012</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>33</Volume>
<Issue>10</Issue>
<PubDate><Year>2019</Year>
<Month>10</Month>
</PubDate>
</JournalIssue>
<Title>Clinical transplantation</Title>
<ISOAbbreviation>Clin Transplant</ISOAbbreviation>
</Journal>
<ArticleTitle>Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.</ArticleTitle>
<Pagination><MedlinePgn>e13689</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/ctr.13689</ELocationID>
<Abstract><AbstractText Label="OBJECTIVES">To describe the incidence of cytomegalovirus (CMV) infection/disease in kidney transplant recipients receiving an mTOR-inhibitor-containing immunosuppressive regimen without prophylactic CMV treatment.</AbstractText>
<AbstractText Label="METHODS">This single-center retrospective cohort analysis included all de novo kidney transplant recipients (09/15/2015-07/31/2017) receiving 3 mg/kg single dose of rabbit antithymocyte globulin induction, tacrolimus, everolimus, and prednisone. Preemptive therapy was initiated only in patients deemed at higher risk for CMV infection: (a) D+/R- CMV patients; (b) after treatment for acute rejection (ARt); and (c) after everolimus discontinuation (EVRd).</AbstractText>
<AbstractText Label="RESULTS">Of 230 patients, there were no episodes of CMV disease among 217 (94%) without criteria to initiate preemptive therapy. Of 77 (33.5%) patients initiating preemptive therapy, 13 were D+/R-, 30 were ARt, and 34 were EVRd. The overall incidence of first CMV infection/disease was 6% (46.1% in D+/R-, 13.3% ARt [all patients had also discontinued everolimus], and 11.8% after early [<90 days] EVRd). The incidence of biopsy-proven acute rejection was 5.6%, and median glomerular filtration rate at month 12 was 47 mL/min/1.73m<sup>2</sup>
 . One-year patient and death-censored graft survivals were 97.4% and 98.1%.</AbstractText>
<AbstractText Label="CONCLUSION">This study suggests that everolimus-containing immunosuppressive regimen reduces the need for preventive strategies for CMV infection in the majority of kidney transplant recipients, reducing antiviral drug-associated toxicities and healthcare-related expenditures.</AbstractText>
<CopyrightInformation>© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cristelli</LastName>
<ForeName>Marina Pontelo</ForeName>
<Initials>MP</Initials>
<AffiliationInfo><Affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Felipe</LastName>
<ForeName>Claudia Rosso</ForeName>
<Initials>CR</Initials>
<AffiliationInfo><Affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Prizmic</LastName>
<ForeName>Paulo Sergio de Souza</ForeName>
<Initials>PSS</Initials>
<AffiliationInfo><Affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>de Azevedo</LastName>
<ForeName>Vega Figueiredo Dourado</ForeName>
<Initials>VFD</Initials>
<AffiliationInfo><Affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Viana</LastName>
<ForeName>Laila Almeida</ForeName>
<Initials>LA</Initials>
<AffiliationInfo><Affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tavares</LastName>
<ForeName>Melissa Gaspar</ForeName>
<Initials>MG</Initials>
<Identifier Source="ORCID">0000-0001-6908-1927</Identifier>
<AffiliationInfo><Affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wagner de Castro Lima Santos</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Infectious Disease Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>de Paula</LastName>
<ForeName>Mayara Ivani</ForeName>
<Initials>MI</Initials>
<AffiliationInfo><Affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Medina-Pestana</LastName>
<ForeName>Jose Osmar</ForeName>
<Initials>JO</Initials>
<AffiliationInfo><Affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tedesco-Silva Junior</LastName>
<ForeName>Helio</ForeName>
<Initials>H</Initials>
<Identifier Source="ORCID">0000-0002-9896-323X</Identifier>
<AffiliationInfo><Affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, São Paulo, SP, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>10</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Denmark</Country>
<MedlineTA>Clin Transplant</MedlineTA>
<NlmUniqueID>8710240</NlmUniqueID>
<ISSNLinking>0902-0063</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000961">Antilymphocyte Serum</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9HW64Q8G6G</RegistryNumber>
<NameOfSubstance UI="D000068338">Everolimus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>D7RD81HE4W</RegistryNumber>
<NameOfSubstance UI="C512542">thymoglobulin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VB0R961HZT</RegistryNumber>
<NameOfSubstance UI="D011241">Prednisone</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>WM0HAQ4WNM</RegistryNumber>
<NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000961" MajorTopicYN="N">Antilymphocyte Serum</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003587" MajorTopicYN="N">Cytomegalovirus</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003586" MajorTopicYN="N">Cytomegalovirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000068338" MajorTopicYN="N">Everolimus</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006085" MajorTopicYN="N">Graft Survival</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">antibiotic prophylaxis</Keyword>
<Keyword MajorTopicYN="Y">clinical trial design</Keyword>
<Keyword MajorTopicYN="Y">cytomegalovirus</Keyword>
<Keyword MajorTopicYN="Y">infection and infectious agents</Keyword>
<Keyword MajorTopicYN="Y">mTOR inhibitors</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year>
<Month>04</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2019</Year>
<Month>07</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2019</Year>
<Month>08</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>8</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>8</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31400155</ArticleId>
<ArticleId IdType="doi">10.1111/ctr.13689</ArticleId>
</ArticleIdList>
<ReferenceList><Title>REFERENCES</Title>
<Reference><Citation>Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900-931.</Citation>
</Reference>
<Reference><Citation>Torre-Cisneros J, Aguado JM, Caston JJ, et al. Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev (Orlando). 2016;30(3):119-143.</Citation>
</Reference>
<Reference><Citation>Hodson EM, Ladhani M, Webster AC, Strippoli GF, Craig JC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013;2:CD003774.</Citation>
</Reference>
<Reference><Citation>Owers DS, Webster AC, Strippoli GF, Kable K, Hodson EM. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013;2:CD005133.</Citation>
</Reference>
<Reference><Citation>Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation. 2012;93(11):1075-1085.</Citation>
</Reference>
<Reference><Citation>Andrassy J, Hoffmann VS, Rentsch M, et al. Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? A systematic review and meta-analysis. Transplantation. 2012;94(12):1208-1217.</Citation>
</Reference>
<Reference><Citation>Tedesco- Silva H, Felipe C, Ferreira A, et al. Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses. Am J Transplant. 2015;15(10):2655-2664.</Citation>
</Reference>
<Reference><Citation>Cervera C, Cofan F, Hernandez C, et al. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis. Transpl Int. 2016;29(11):1216-1225.</Citation>
</Reference>
<Reference><Citation>Kho MM, Bouvy AP, Cadogan M, Kraaijeveld R, Baan CC, Weimar W. The effect of low and ultra-low dosages thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients. Transpl Immunol. 2012;26(4):186-190.</Citation>
</Reference>
<Reference><Citation>Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.</Citation>
</Reference>
<Reference><Citation>Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753-760.</Citation>
</Reference>
<Reference><Citation>Heldenbrand S, Li C, Cross RP, et al. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients. Transpl Infect Dis. 2016;18(6):904-912.</Citation>
</Reference>
<Reference><Citation>Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant. 2011;11(11):2453-2462.</Citation>
</Reference>
<Reference><Citation>Pascual J, Berger SP, Witzke O, et al. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol. 2018;29(7):1979-1991.</Citation>
</Reference>
<Reference><Citation>Basso G, Felipe CR, Cristelli MP, et al. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis. Transpl Infect Dis. 2018;20(4):e12919.</Citation>
</Reference>
<Reference><Citation>Havenith SHC, Yong SL, van Donselaar-van der Pant KA, van Lier RAW, ten Berge IJM, Bemelman FJ. Donselaar-van der Pant KA, van Lier RA, ten Berge IJ, Bemelman FJ. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients. Transplantation. 2013;95(1):184-191.</Citation>
</Reference>
<Reference><Citation>Cristelli MP, Esmeraldo RM, Pinto CM, et al. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients. Transpl Infect Dis. 2018;20(4):e12907.</Citation>
</Reference>
<Reference><Citation>Harari A, Zimmerli SC, Pantaleo G. Cytomegalovirus (CMV)-specific cellular immune responses. Hum Immunol. 2004;65(5):500-506.</Citation>
</Reference>
<Reference><Citation>Bak S, Tischer S, Dragon A, et al. Selective Effects of mtor inhibitor sirolimus on naïve and CMV-specific T cells extending its applicable range beyond immunosuppression. Front Immunol. 2018;9:2953.</Citation>
</Reference>
<Reference><Citation>Lee Y-M, Kim YH, Han DJ, et al. Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients. Transpl Infect Dis. 2014;16(3):397-402.</Citation>
</Reference>
<Reference><Citation>Shihab F, Qazi Y, Mulgaonkar S, et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of tacrolimus. Am J Transplant. 2017;17(9):2363-2371.</Citation>
</Reference>
<Reference><Citation>Kaplan B, Schold J, Srinivas T, et al. Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Transplant. 2004;4(10):1709-1712.</Citation>
</Reference>
<Reference><Citation>Budde K, Zeier M, Witzke O, et al. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. Nephrol Dial Transplant. 2017;32(6):1060-1070.</Citation>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Brésil</li>
</country>
<region><li>État de São Paulo</li>
</region>
<settlement><li>São Paulo</li>
</settlement>
<orgName><li>Université de São Paulo</li>
</orgName>
</list>
<tree><country name="Brésil"><region name="État de São Paulo"><name sortKey="Cristelli, Marina Pontelo" sort="Cristelli, Marina Pontelo" uniqKey="Cristelli M" first="Marina Pontelo" last="Cristelli">Marina Pontelo Cristelli</name>
</region>
<name sortKey="De Azevedo, Vega Figueiredo Dourado" sort="De Azevedo, Vega Figueiredo Dourado" uniqKey="De Azevedo V" first="Vega Figueiredo Dourado" last="De Azevedo">Vega Figueiredo Dourado De Azevedo</name>
<name sortKey="De Paula, Mayara Ivani" sort="De Paula, Mayara Ivani" uniqKey="De Paula M" first="Mayara Ivani" last="De Paula">Mayara Ivani De Paula</name>
<name sortKey="Felipe, Claudia Rosso" sort="Felipe, Claudia Rosso" uniqKey="Felipe C" first="Claudia Rosso" last="Felipe">Claudia Rosso Felipe</name>
<name sortKey="Medina Pestana, Jose Osmar" sort="Medina Pestana, Jose Osmar" uniqKey="Medina Pestana J" first="Jose Osmar" last="Medina-Pestana">Jose Osmar Medina-Pestana</name>
<name sortKey="Prizmic, Paulo Sergio De Souza" sort="Prizmic, Paulo Sergio De Souza" uniqKey="Prizmic P" first="Paulo Sergio De Souza" last="Prizmic">Paulo Sergio De Souza Prizmic</name>
<name sortKey="Tavares, Melissa Gaspar" sort="Tavares, Melissa Gaspar" uniqKey="Tavares M" first="Melissa Gaspar" last="Tavares">Melissa Gaspar Tavares</name>
<name sortKey="Tedesco Silva Junior, Helio" sort="Tedesco Silva Junior, Helio" uniqKey="Tedesco Silva Junior H" first="Helio" last="Tedesco-Silva Junior">Helio Tedesco-Silva Junior</name>
<name sortKey="Viana, Laila Almeida" sort="Viana, Laila Almeida" uniqKey="Viana L" first="Laila Almeida" last="Viana">Laila Almeida Viana</name>
<name sortKey="Wagner De Castro Lima Santos, Daniel" sort="Wagner De Castro Lima Santos, Daniel" uniqKey="Wagner De Castro Lima Santos D" first="Daniel" last="Wagner De Castro Lima Santos">Daniel Wagner De Castro Lima Santos</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000183 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000183 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:31400155
   |texte=   Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:31400155" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020

	Serveur d'exploration sur la rapamycine et les champignons
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la rapamycine et les champignons

Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.

Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki